Fed Governor Adriana Kugler to resign
LEIDEN, Netherlands & CAMBRIDGE, Mass. - ProQR Therapeutics NV (NASDAQ:PRQR), a biotech firm focused on RNA therapies, today announced strategic appointments to its executive team, naming Dennis Hom as Chief Financial Officer and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer. These appointments come as the company prepares to advance its proprietary Axiomer™ RNA editing platform into clinical stages.
Dennis Hom, with a 25-year tenure in financial leadership roles, joins ProQR from Sagimet Biosciences, where he was instrumental in leading the company through financings, including an IPO, and a significant licensing transaction. Hom’s background includes positions at Amgen, Novartis, and investment banking at Hambrecht & Quist, Chase, and JP Morgan.
Dr. Cristina Lopez Lopez brings over two decades of experience in translational R&D, most recently serving as Global Head of Neurodegeneration at Johnson & Johnson. Her career includes senior roles at Roche and Novartis, with a focus on biomarker strategies and patient-centric therapeutic development.
The incoming executives are set to replace Jurriaan Dekkers, the outgoing CFO, and René Beukema, the outgoing Chief Corporate Development Officer, who will remain during a transitional period for continuity. Daniel A. de Boer, CEO of ProQR, expressed gratitude for their contributions to the company’s strategic transition.
ProQR’s Axiomer™ technology aims to harness the body’s own RNA editing mechanisms to correct mutations or modulate protein expression, potentially offering new treatments for a variety of diseases. The company’s pipeline is growing, targeting both rare and prevalent diseases with unmet needs.
This leadership transition is indicative of ProQR’s commitment to moving its Axiomer platform and RNA editing programs forward. The information in this article is based on a press release statement.
In other recent news, ProQR Therapeutics has caught the attention of multiple analyst firms with its promising developments. Raymond James has maintained a Strong Buy rating with a $14 price target, highlighting ProQR’s clinical progress and solid financials after its fourth-quarter earnings report. The company reported collaboration revenue of €4.3 million and operating expenses of €14.5 million, with an earnings per share (EPS) of €(0.09) for the fourth quarter of 2024. ProQR’s cash and cash equivalents were reported at €149.4 million, providing a stable financial outlook into mid-2027.
H.C. Wainwright has raised ProQR’s stock target to $12, maintaining a Buy rating due to the potential of the company’s Axiomer technology, especially for its lead program AX-0810 targeting Primary Sclerosing Cholangitis. Citi has upgraded ProQR to a Buy with a $4 price target, noting the market’s minimal current valuation of AX-0810 despite its significant potential. The company plans to submit a Clinical Trial Application for AX-0810 in the second quarter of 2025, with top-line data expected by the year’s end.
Jones Trading has initiated coverage on ProQR with a Buy rating and an $11 price target, citing the company’s focus on RNA therapeutics and its promising pipeline. The firm projects a peak unadjusted revenue of $3.9 billion by 2036 for the PSC program, assigning a 15% probability of success. ProQR’s collaboration with Eli Lilly further underscores the potential value of its platform. These recent developments reflect a positive outlook from analysts on ProQR’s future within the RNA editing industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.